Breaking News Instant updates and real-time market news.

MDT

Medtronic

$97.85

0.38 (0.39%)

12:26
09/23/18
09/23
12:26
09/23/18
12:26

Clinical study shows safety, efficacy outcomes for Medtronic Resolute Onyx DES

Investigators unveiled new clinical data from the physician-initiated BIONYX study, representing the first all-comers analysis in nearly 2,500 patients comparing the safety and efficacy of the durable polymer Resolute Onyx drug-eluting stent from Medtronic to the Orsiro biodegradable polymer stent. At one year, the study showed patients with coronary artery disease who were treated with Orsiro BP-DES received no clinical advantage compared to patients treated with the Resolute Onyx DP-DES, and Orsiro BP-DES demonstrated a higher rate of stent thrombosis. Enrolling approximately 2,500 real-world patients, the BIONYX study had a primary composite endpoint of target vessel failure at one-year and showed no statistically significant difference in outcomes for the Resolute Onyx DP-DES treated group at 4.5% compared to 4.7% with the Orsiro BP-DES. However, notable differences were observed in significantly lower rates of definite or probable stent thrombosis at one year. The Resolute Onyx DES is coated with the proprietary BioLinx polymer, a bio-compatible and non-thrombogenic coating specifically designed for use on DES. Low rates of stent thrombosis have been observed in more than 70,000 real-world clinical study patients, with additional studies underway, including the global Medtronic Onyx ONE Month DAPT Program comprised of two studies designed to investigate safety following one-month of dual anti-platelet therapy discontinuation post-PCI. The Resolute Onyx DES offers the broadest size matrix available and is the first-and-only DES to feature Core Wire Technology which enables thinner struts and greater deliverability while maintaining structural strength and enhanced visibility.

  • 09

    Oct

MDT Medtronic
$97.85

0.38 (0.39%)

09/13/18
PIPR
09/13/18
NO CHANGE
Target $58
PIPR
Overweight
Globus Medical Nemaris acquisition to be modest contributor, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien kept his Overweight rating and $58 price target on Globus Medical (GMED), saying the company's acquisition of Nemaris announced earlier today should be a "modest revenue contributor". The analyst estimates the price tag around $20M. Longer term, the analyst expects Nemaris' marketed Surgimap to bring help to the company in terms of staying ahead of Medtronic (MDT) in the surgical planning category.
09/21/18
PIPR
09/21/18
NO CHANGE
Target $105
PIPR
Overweight
Medtronic acquisition of Mazor not a surprise, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien believes Medtronic's (MDT) $1.64B acquisition of Mazor Robotics (MZOR) is not much of a surprise given the companies' exclusive distribution arrangement and Medtronic's existing minority stake. The deal will help Medtronic's spine franchise business stay on the road to recovery, O'Brien tells investors in a research note. He keeps an Overweight rating on the shares with a $105 price target. Further, the analyst believes robot placements are "still in the early days" and that the acquisition will not "overly hurt" Globus Medical's (GMED) ability to sell systems in coming quarters. As such, O'Brien thinks the Mazor Robotics takeover will unlikely have an impact on Globus's Excelsius robot.
09/21/18
NEED
09/21/18
UPGRADE
NEED
Hold
Mazor Robotics upgraded to Hold from Underperform at Needham
Needham analyst Mike Matson upgraded Mazor Robotics (MZOR) to Hold from Underperform after its announced acquisition by Medtronic (MDT). The analyst notes that other bidders are unlikely to emerge given that Medtronic is "currently the exclusive global distributor of the Mazor X spinal robotics system" and already owns a significant part of the company. Matson adds that since the two companies do not compete in the same segment of the spine market, any anti-trust issues are unlikely to emerge in the regulatory review.
09/21/18
STFL
09/21/18
NO CHANGE
Target $70
STFL
Buy
IntriCon price target raised to $70 from $65 at Stifel
Stifel analyst Jonathan Block raised his price target on IntriCon (IIN) to $70 from $65 by assigning what he called "relatively conservative sales multiples" to his forecasts for the company's Medical and Hearing businesses, but he also contends that margin expansion will play an important part to IntriCon's story in the coming years, giving the stock a path toward $100 per share. Block, who believes IntriCon's traction with Medtronic (MDT) gives it a long runway for growth, keeps a Buy rating on the shares.

TODAY'S FREE FLY STORIES

SHLD

Sears

$0.40

0.05 (14.28%)

05:14
10/15/18
10/15
05:14
10/15/18
05:14
Hot Stocks
Breaking Hot Stocks news story on Sears »

Sears files voluntary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALK

Alaska Air

$61.57

1.75 (2.93%)

05:12
10/15/18
10/15
05:12
10/15/18
05:12
Recommendations
Alaska Air analyst commentary  »

Alaska Air deserves…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

  • 27

    Nov

CTMX

CytomX Therapeutics

$15.76

0.44 (2.87%)

05:09
10/15/18
10/15
05:09
10/15/18
05:09
Initiation
CytomX Therapeutics initiated  »

CytomX Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TPR

Tapestry

$43.81

1.13 (2.65%)

05:08
10/15/18
10/15
05:08
10/15/18
05:08
Downgrade
Tapestry rating change  »

Tapestry downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

EB

Eventbrite

$28.12

0.23 (0.82%)

05:04
10/15/18
10/15
05:04
10/15/18
05:04
Initiation
Eventbrite initiated  »

Eventbrite initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ELAN

Elanco

$32.66

0.31 (0.96%)

05:02
10/15/18
10/15
05:02
10/15/18
05:02
Initiation
Elanco initiated  »

Elanco initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

ZTS

Zoetis

$88.90

1.84 (2.11%)

04:59
10/15/18
10/15
04:59
10/15/18
04:59
Upgrade
Zoetis rating change  »

Zoetis upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

KSU

Kansas City Southern

$102.56

-0.41 (-0.40%)

04:57
10/15/18
10/15
04:57
10/15/18
04:57
Upgrade
Kansas City Southern rating change  »

Kansas City Southern…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 06

    Nov

04:55
10/15/18
10/15
04:55
10/15/18
04:55
General news
Breaking General news story  »

4-Week Bill Announcement…

04:55
10/15/18
10/15
04:55
10/15/18
04:55
General news
Breaking General news story  »

8-Week Bill Announcement…

REFR

Research Frontiers

$1.73

0.03 (1.76%)

04:55
10/15/18
10/15
04:55
10/15/18
04:55
Conference/Events
Research Frontiers management to meet with Maxim »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

TEUM

Pareteum

$2.55

0.02 (0.79%)

04:55
10/15/18
10/15
04:55
10/15/18
04:55
Conference/Events
Pareteum management to meet with Lake Street »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 16

    Oct

  • 07

    Nov

  • 15

    Nov

IHRT

iHeartMedia

$0.00

(0.00%)

04:55
10/15/18
10/15
04:55
10/15/18
04:55
Conference/Events
Cowen TMT analyst Vitanza to hold an analyst/industry conference call »

Technology, Media and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

OKE

Oneok

$64.99

-0.24 (-0.37%)

04:55
10/15/18
10/15
04:55
10/15/18
04:55
Conference/Events
Oneok management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 16

    Oct

  • 31

    Oct

FDX

FedEx

$220.97

3.54 (1.63%)

04:55
10/15/18
10/15
04:55
10/15/18
04:55
Conference/Events
FedEx management to meet with Stephens »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

HRS

Harris

$154.88

0.61 (0.40%)

, LLL

L3 Technologies

$195.99

0.74 (0.38%)

04:55
10/15/18
10/15
04:55
10/15/18
04:55
Conference/Events
L3 Technologies and Harris to hold a joint conference call »

The companies hold a…

HRS

Harris

$154.88

0.61 (0.40%)

LLL

L3 Technologies

$195.99

0.74 (0.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 15

    Oct

  • 16

    Oct

04:55
10/15/18
10/15
04:55
10/15/18
04:55
General news
Breaking General news story  »

6-Month Bill Auction to…

NXST

Nexstar

$74.10

0.2 (0.27%)

04:55
10/15/18
10/15
04:55
10/15/18
04:55
Conference/Events
Nexstar management to meet with B. Riley FBR »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 08

    Nov

  • 13

    Nov

SLDB

Solid Biosciences

$34.19

-0.15 (-0.44%)

04:55
10/15/18
10/15
04:55
10/15/18
04:55
Conference/Events
Solid Biosciences has a conference call hosted by JPMorgan »

JPMorgan Analyst Rama…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

GOL

Gol Linhas

$7.38

0.27 (3.80%)

04:55
10/15/18
10/15
04:55
10/15/18
04:55
Conference/Events
Gol Linhas management to meet with Buckingham »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 16

    Oct

ADBE

Adobe

$248.89

10.24 (4.29%)

04:55
10/15/18
10/15
04:55
10/15/18
04:55
Conference/Events
Adobe to host financial analyst meeting »

Financial Analyst Meeting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

AET

Aetna

$200.91

1.83 (0.92%)

, CVS

CVS Health

$74.49

1.33 (1.82%)

04:55
10/15/18
10/15
04:55
10/15/18
04:55
Conference/Events
Cowen healthcare analysts to hold an analyst/industry conference call »

Healthcare Analysts,…

AET

Aetna

$200.91

1.83 (0.92%)

CVS

CVS Health

$74.49

1.33 (1.82%)

ESRX

Express Scripts

$94.29

0.55 (0.59%)

CI

Cigna

$207.05

1.04 (0.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 15

    Oct

  • 15

    Oct

  • 01

    Nov

AET

Aetna

$200.91

1.83 (0.92%)

, CVS

CVS Health

$74.49

1.33 (1.82%)

04:55
10/15/18
10/15
04:55
10/15/18
04:55
Conference/Events
Cowen pharmaceuticals analyst to hold an analyst/industry conference call »

Healthcare Analysts,…

AET

Aetna

$200.91

1.83 (0.92%)

CVS

CVS Health

$74.49

1.33 (1.82%)

ESRX

Express Scripts

$94.29

0.55 (0.59%)

CI

Cigna

$207.05

1.04 (0.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 15

    Oct

  • 15

    Oct

  • 01

    Nov

04:55
10/15/18
10/15
04:55
10/15/18
04:55
Conference/Events
Morgan Stanley China auto analysts to hold analyst/industry conference call »

U.S. Autos & Shared…

04:55
10/15/18
10/15
04:55
10/15/18
04:55
Conference/Events
Cowen pharmaceuticals analyst to hold an analyst/industry conference call »

Pharmaceuticals Analyst…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.